<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03759782</url>
  </required_header>
  <id_info>
    <org_study_id>20180733</org_study_id>
    <nct_id>NCT03759782</nct_id>
  </id_info>
  <brief_title>Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity</brief_title>
  <official_title>Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus (HBV) leads to life-threatening disease like liver failure and liver
      cancer. For most, a cure is unattainable as current HBV antiviral therapy (using nucleoside
      analogues) are not able to clear the virus from their liver. While HBV treatments are
      typically administered alone (monotherapy), this study will explore the use of Ribavirin in
      combination with standard therapy to enhance current treatment regimens. Ribavirin is
      commonly used to treat Hepatitis C Virus (HCV) but there is evidence that Ribavirin also
      induces immune effects that are beneficial in HBV treatment. The aim of this study is to
      determine whether combination of Ribavirin and a nucleoside analog is more effective compared
      to nucleoside analog treatment alone. Enrolled patients will be followed for treatment
      response according to standard clinical and virological tests, as well as immune response to
      HBV. Our ultimate goal is to find a more effective treatment and improve health outcomes for
      persons living with HBV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Decline of Participants Serum HBV DNA values for both study arms at each study.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The absolute decline in HBV DNA and quantitative HBsAg titre will be compared with baseline level at each study visit overall and between study arms (with or without RBV).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroscan score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Individual fibroscan scores pre and post treatment for each group, using fibrosis scores calculated in kilopascal F0 representing no fibrosis and F4 value indicating cirrhosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme values</measure>
    <time_frame>24 weeks</time_frame>
    <description>Participants individual reduction in liver enzymes at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>28 weeks</time_frame>
    <description>Safety profile of TDF plus Ribavirin regime</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir (TDF) 300 mg po once a day (OD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if &lt;70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir as per standard of care</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HBV Hepatitis B surface antigen (HBsAg) positive for a minimum of 24 weeks

          2. HBV Hepatitis B antigen (HBeAg) positive /Hepatitis e antibody (eAb) negative

          3. HBV DNA level &gt;20,000 IU/mL

          4. ≥ 18 years of age

        Exclusion Criteria:

          1. Willingness and ability to sign an informed consent

          2. HBV nucleos(t)ides and/or interferon exposure within 24 weeks of study medication
             dosing

          3. HIV and other immune compromising condition (e.g. cancer with the exception of
             non-invasive cutaneous malignancy, autoimmune condition) or therapy (i.e. systemic
             steroids, chemotherapy)

          4. HCV co-infected

          5. Cirrhosis (defined by biopsy criteria or as &gt;18.4 kilopascal (kPa) by transient
             elastography)

          6. Creatinine Clearance &lt;60 ml/min

          7. Baseline hemoglobin &lt;130 g/L in males and &lt;120 g/L in females

          8. Unwilling or unable to use contraception (unless confirmed surgical sterilization)

          9. Pregnancy confirmed by blood test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curtis L Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Curtis L Cooper, MD</last_name>
    <phone>613.737.8924</phone>
    <email>ccooper@toh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam I Muir, RN BA</last_name>
    <phone>613737.8899</phone>
    <phone_ext>72723</phone_ext>
    <email>mimmuir@toh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Cooper, MD</last_name>
      <phone>6137378924</phone>
      <email>ccooper@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Muir, RN</last_name>
      <phone>6137378899</phone>
      <phone_ext>72723</phone_ext>
      <email>mmuir@toh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

